New drug obrixtamig targets Hard-to-Treat lung and neuroendocrine cancers in first human trial
NCT ID NCT04429087
First seen Nov 01, 2025
Summary
This early-phase study tests obrixtamig, a drug that helps the immune system attack cancer cells, in adults with advanced small cell lung cancer or other neuroendocrine cancers that have a specific marker called DLL3. Participants receive the drug weekly or every three weeks for up to 3 years. The main goal is to find the highest safe dose and schedule.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PATIENTS WITH SMALL CELL LUNG CARCINOMA AND OTHER NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clínica Universidad de Navarra
RECRUITINGPamplona, 31008, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Clinico Universitario de Valencia
RECRUITINGValencia, 46010, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Universitari Vall d'Hebron
RECRUITINGBarcelona, 08035, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital del Mar
RECRUITINGBarcelona, 08003, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Cancer Center Hospital East
RECRUITINGChiba, Kashiwa, 277-8577, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Technische Universität Dresden
RECRUITINGDresden, 01307, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Maryland School of Medicine
RECRUITINGBaltimore, Maryland, 21201, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Pittsburgh Medical Center
COMPLETEDPittsburgh, Pennsylvania, 15232, United States
-
Universitätsklinikum Köln (AöR)
COMPLETEDCologne, 50937, Germany
-
Universitätsklinikum Würzburg AÖR
RECRUITINGWürzburg, 97078, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63108, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Winship Cancer Institute
RECRUITINGAtlanta, Georgia, 30322, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.